
CORRIGENDUM TO THE GRANT OF EMPLOYEE SHARE OPTIONS PURSUANT TO THE SMG SHARE OPTION SCHEME

The Board of Directors (the “**Board**”) of Singapore Medical Group Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) refers to the announcement released on 24 May 2022 relating to the grant of employee share options pursuant to the SMG Share Option Scheme.

The Company wishes to clarify that the number of Options granted was 930,000 and not 780,000 as announced on 24 May 2022. The 930,000 Options amounts to 0.19% of the total number of issued shares of the Company (excluding treasury shares).

The revised details of the grant of Options are as follows:

		Grant of Options
1	Date of Grant	24 May 2022
2	Exercise Price of Options granted	S\$0.309
3	Number of Options granted	930,000
4	Market price of the Company's Shares on the Date of Grant ¹	S\$0.309
5	Number of Options granted to each Director and Controlling Shareholder, if any	None
6	Validity period of the Options	5 years from Date of Grant
7	Exercise Period of the Options	<p>The Options shall only be exercised after the first anniversary of the Date of Grant of the Option(s) subject to the following:</p> <ul style="list-style-type: none">- the option over up to one third only of the Shares comprised in the Option(s) may be exercised after the first anniversary of the Date of Grant of the Option(s);- the option over up to two thirds only of the Shares comprised in the Option(s) may be exercised after the second anniversary of the Date of Grant of the Option(s); and- the option over all of the Shares comprised in the Option(s) may be exercised after the third anniversary of the Date of Grant of the Option(s), <p>provided always that Options shall be exercised before the fifth anniversary of the relevant Date of Grant or such earlier date as may be determined by the Committee, failing which all unexercised Options shall immediately lapse and become null and void and the Option Holder shall have no claim against the Company.</p>

¹ The market price is equal to the average of the closing price of the Company's shares on the SGX-ST over the 5 consecutive trading days immediately preceding the Date of Grant as defined in Employee Share Option Scheme.

By Order of the Board

Dr Beng Teck Liang

Executive Director and Chief Executive Officer

8 July 2022

*This announcement has been prepared by Singapore Medical Group Limited (the “**Company**”) and its contents have been reviewed by the Company’s sponsor, UOB Kay Hian Private Limited (the “**Sponsor**”) for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) Listing Manual Section B: Rules of Catalist.*

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Lance Tan, Senior Vice President, at 8 Anthony Road, #01-01, Singapore 229957, telephone (65) 6590 6881.